Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:14 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Treatment of Nodding Syndrome - A Randomized Blinded Placebo-Controlled Crossover Trial of Oral Pyridoxine and Conventional Anti-Epileptic Therapy, in Northern Uganda - 2012
NCT01730313 · Centers for Disease Control and Prevention · PHASE2 · withdrawn · last registry update 2022-05-18 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Did not get approval from the collaborating partners in-country” | – | Registry record, Centers for Disease Control and Prevention |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ALDH5A1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-05-17Results posted on the registry: Universidad Autonoma de San Luis Potosí, Valproate Sodium + Memantine (NCT04698525)
- 2023-05-17Results posted on the registry: Intra-Cellular Therapies, Inc., Lumateperone (ITI-007) + Placebo (NCT02600507)
- 2023-03-31Also stopped (withdrawn): University of Miami, Valproate + Quetiapine (NCT04513314)
- 2023-02-10Phase 3 first posted: Tanta University, Levetiracetam &/or sodium valproate + Metformin (NCT05722951)
- 2022-11-14Results posted on the registry: Frequency Therapeutics, FX-322 + Placebo (NCT03616223)
- 2022-11-02Phase 3 first posted: Dr. Inge Winter, Clozapine + Esketamine Nasal Product (NCT05603104)
- 2022-06-27Also stopped (withdrawn): Assistance Publique Hopitaux De Marseille, Perampanel + conventional antiepileptic treatment (NCT03636958)
- 2022-06-24Phase 3 first posted: M.D. Anderson Cancer Center, Haloperidol + Chlorpromazine (NCT05431595)
- 2022-03-24Results posted on the registry: Mayo Clinic, Gabapentin + Benzodiazepines (NCT03012815)
- 2022-03-02Phase 3 first posted: University of Southern Denmark, Rapid sedation (NCT05263674)
- 2022-02-17Results posted on the registry: Mazandaran University of Medical Sciences, Levetiracetam + Valproate (NCT03940326)
- 2021-12-01Results posted on the registry: Norwegian University of Science and Technology, Betablockers or other preventive drugs based on primary headache type (NCT00159588)
- 2021-10-29Also stopped (withdrawn): Westat, Valproic Acid Solution + Isotonic saline solution (NCT04531579)
- 2021-10-29Also stopped (withdrawn): Westat, Valproic acid + Isotonic saline solution (NCT04531592)
- 2021-10-28Results posted on the registry: Virginia Commonwealth University, sorafenib tosylate + valproic acid (NCT01817751)
- 2021-10-08Also stopped (withdrawn): University of British Columbia, Pantoprazole + Pantoprazole (NCT02213887)
- 2021-10-07Results posted on the registry: Kimberly S Jones, Valproic Acid (VPA) + Dihydroergotamine (DHE) (NCT03885154)
- 2021-10-07Also stopped (terminated): Kimberly S Jones, Valproic Acid (VPA) + Dihydroergotamine (DHE) (NCT03885154)
- 2021-09-24Also stopped (terminated): Rambam Health Care Campus, Paracetamol + Antiepileptic (either carbamazepine, lamotrigine, phenytoin or valproic acid) (NCT03161509)
- 2021-08-12Also stopped (terminated): University of Michigan, a drug against ALDH5A1 (NCT04251234)
- 2021-07-21Results posted on the registry: Baylor College of Medicine, Valproic acid + Bevacizumab (NCT00879437)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision